Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hedyeh Ebrahimi

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Cancer Medicine|March 27, 2025
Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and InclusionBenjamin D Mercier, Ameish Govindarajan, Daniela V Castro, et al.
European Urology Focus|December 8, 2024
Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell CarcinomaJustine Panian, Caiwei Zhong, Sharon H Choi, et al.
Clinical Genitourinary Cancer|June 10, 2023
Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer ResearchHedyeh Ebrahimi, Daniela V Castro, Matthew I Feng, et al.
European Urology Oncology|January 7, 2023
Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell CarcinomaZeynep B Zengin, Ameish Govindarajan, Nicholas Salgia, et al.
Cancers|June 12, 2026
Evaluating Worldwide Disparities in Bladder Cancer Clinical Trial AvailabilityKoral U Shah, Daniela V Castro, Xiaochen Li, et al.
BJU International|August 7, 2023
Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapyDaniela V Castro, Sweta R Prajapati, Matthew I Feng, et al.
JAMA Network Open|April 15, 2026
Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell CarcinomaMartin Zarba, Eddy Saad, Karl Semaan, et al.
Nature Medicine|June 28, 2024
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trialHedyeh Ebrahimi, Nazli Dizman, Luis Meza, et al.
Cancer Cell|August 8, 2025
Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinomaNicholas J Salgia, Adil Khan, Wilhelm M Aubrecht, et al.
Archives of Iranian Medicine|July 27, 2017
Disability-Adjusted Life-Years (DALYs) for 315 Diseases and Injuries and Healthy Life Expectancy (HALE) in Iran and its Neighboring Countries, 1990-2015: Findings from Global Burden of Disease Study 2015Sadaf G Sepanlou, Mahboubeh Parsaeian, Kristopher J Krohn, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Cancer Medicine|March 27, 2025
Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and InclusionBenjamin D Mercier, Ameish Govindarajan, Daniela V Castro, et al.
European Urology Focus|December 8, 2024
Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell CarcinomaJustine Panian, Caiwei Zhong, Sharon H Choi, et al.
Clinical Genitourinary Cancer|June 10, 2023
Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer ResearchHedyeh Ebrahimi, Daniela V Castro, Matthew I Feng, et al.
European Urology Oncology|January 7, 2023
Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell CarcinomaZeynep B Zengin, Ameish Govindarajan, Nicholas Salgia, et al.
Cancers|June 12, 2026
Evaluating Worldwide Disparities in Bladder Cancer Clinical Trial AvailabilityKoral U Shah, Daniela V Castro, Xiaochen Li, et al.
BJU International|August 7, 2023
Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapyDaniela V Castro, Sweta R Prajapati, Matthew I Feng, et al.
JAMA Network Open|April 15, 2026
Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell CarcinomaMartin Zarba, Eddy Saad, Karl Semaan, et al.
Nature Medicine|June 28, 2024
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trialHedyeh Ebrahimi, Nazli Dizman, Luis Meza, et al.
Cancer Cell|August 8, 2025
Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinomaNicholas J Salgia, Adil Khan, Wilhelm M Aubrecht, et al.
Archives of Iranian Medicine|July 27, 2017
Disability-Adjusted Life-Years (DALYs) for 315 Diseases and Injuries and Healthy Life Expectancy (HALE) in Iran and its Neighboring Countries, 1990-2015: Findings from Global Burden of Disease Study 2015Sadaf G Sepanlou, Mahboubeh Parsaeian, Kristopher J Krohn, et al.
Pageof 5